[1]张 斌,刘宿慧,余长寿.孟鲁司特联合噻托溴铵对COPD患者血清细胞因子、血液流变学及肺功能的影响[J].医学信息,2020,33(02):144-146.[doi:10.3969/j.issn.1006-1959.2020.02.043]
　ZHANG Bin,LIU Su-hui,YU Chang-shou.Effect of Montelukast Combined with Tiotropium Bromide on Serum Cytokines,Hemorheology and Lung Function in Patients with COPD[J].Medical Information,2020,33(02):144-146.[doi:10.3969/j.issn.1006-1959.2020.02.043]
点击复制

孟鲁司特联合噻托溴铵对COPD患者血清细胞因子、血液流变学及肺功能的影响()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
33卷
期数:
2020年02期
页码:
144-146
栏目:
药物与临床
出版日期:
2020-01-15

文章信息/Info

Title:
Effect of Montelukast Combined with Tiotropium Bromide on Serum Cytokines,Hemorheology and Lung Function in Patients with COPD
文章编号:
1006-1959（2020）02-0144-03
作者:
张 斌; 刘宿慧; 余长寿
（奉新县人民医院内二科，江西 奉新 330700）
Author(s):
ZHANG Bin; LIU Su-hui; YU Chang-shou
(Department of Internal Medicine,Subject Two,Fengxin County People’s Hospital,Fengxin 330700,Jiangxi,China)
关键词:
孟鲁司特; 噻托溴铵; 慢性阻塞性肺疾病; 肺功能
Keywords:
Montelukast; Tiotropium bromide; Chronic obstructive pulmonary disease; Lung function
分类号:
R563
DOI:
10.3969/j.issn.1006-1959.2020.02.043
文献标志码:
A
摘要:
目的 探讨孟鲁司特联合噻托溴铵对慢性阻塞性肺疾病（COPD）患者血清APN、IL-10、TNF-α水平、血液流变学及肺功能的影响。方法 将2016年12月~2018年12月于我院就诊COPD的84例患者纳入研究，随机分为对照组和观察组，每组42例。对照组给予噻托溴铵治疗，观察组给予孟鲁司特联合噻托溴铵治疗。比较两组治疗前后的血清脂联素（APN）、白介素 10（IL-10）、肿瘤坏死因子α（TNF-α），肺功能指标，血液流变学指标。结果 治疗后两组血清APN、IL-10、TNF-α水平下降，且观察组低于对照组，差异有统计学意义（P＜0.05）；治疗后两组用力肺活量（FVC）、第1秒用力呼气容积（FEV1）、每分钟最大通气量（MVV）均上升，且观察组优于对照组，差异有统计学意义（P＜0.05）；治疗后两组纤维蛋白原、红细胞压积、血浆黏度下降，且观察组低于对照组，差异有统计学意义（P＜0.05）。结论 孟鲁司特联合噻托溴铵治疗COPD有助于改善血清APN、IL-10、TNF-α水平、血液流变学指标，促进肺功能的恢复，提高生活质量，具有一定临床应用价值。
Abstract:
Objective To investigate the effects of montelukast combined with tiotropium bromide on serum APN, IL-10, TNF-α levels, hemorheology and pulmonary function in patients with chronic obstructive pulmonary disease (COPD). Methods A total of 84 patients with COPD who were treated in our hospital from December 2016 to December 2018 were included in the study and randomly divided into a control group and an observation group, with 42 patients in each group. The control group was treated with tiotropium bromide, and the observation group was treated with montelukast combined with tiotropium bromide. The serum adiponectin (APN), interleukin 10 (IL-10), tumor necrosis factor alpha (TNF-α), lung function index, and hemorheology index were compared between the two groups before and after treatment.Results After treatment, the levels of serum APN, IL-10, and TNF-α decreased in the two groups, and the observation group was lower than the control group,the difference was statistically significant(P<0.05);Forced vital capacity (FVC), forced expiratory volume (FEV1), and maximum ventilation per minute (MVV) in the two groups increased after treatment, and the observation group was better than the control group,the differences were statistically significant(P<0.05); After treatment, the fibrinogen, hematocrit, and plasma viscosity of the two groups decreased, and the observation group was lower than the control group,the differences were statistically significant (P<0.05).Conclusion Montelukast combined with tiotropium bromide in the treatment of COPD can improve serum APN, IL-10, TNF-α levels, hemorheology indexes, promote pulmonary function recovery, improve quality of life, and have certain clinical application value.

参考文献/References:

[1]陈荣昌.慢性阻塞性肺疾病最新诊治和研究进展[J].华西医学,2018,33(1):15-18. [2]魏海霞,宋永娜.噻托溴铵联合舒利迭治疗慢性阻塞性肺疾病稳定期患者的临床疗效研究[J].现代诊断与治疗,2018,29(23):3822-3823. [3]左晟,马红映,孔志斌,等.孟鲁司特在慢性阻塞性肺疾病稳定期患者中的应用[J].临床肺科杂志,2016,21(10):1817-1820. [4]周丹阳,毛山.2017版慢性阻塞性肺疾病全球倡议更新解读[J].世界临床药物,2018,39(1):1-5. [5]张小娥,张彩莲.慢性阻塞性肺疾病流行病学及疾病经济负担研究进展[J].中国慢性病预防与控制,2017,25(6):472-476. [6]厉旭光,盖磊,周红瑜,等.噻托溴铵联合糖皮质激素治疗慢性阻塞性肺疾病的临床研究[J].实用药物与临床,2018,21(11):1236-1239. [7]胡倩婧.孟鲁司特对稳定期慢性阻塞性肺疾病患者呼吸困难和肺功能的改善作用[J].慢性病学杂志,2019,20(1):115-116,119. [8]阮国虎,李欢.IL-10与慢性阻塞性肺疾病严重程度的关系[J].临床肺科杂志,2019,24(4):669-672.

相似文献/References:

[1]陈文福.噻托溴铵治疗稳定期慢性阻塞性肺疾病的临床疗效分析[J].医学信息,2018,31(02):124.[doi:10.3969/j.issn.1006-1959.2018.02.045]
　CHEN Wen-fu.Clinical Analysis of Tiotropium Bromide in the Treatment of Stable Chronic Obstructive Pulmonary Disease[J].Medical Information,2018,31(02):124.[doi:10.3969/j.issn.1006-1959.2018.02.045]
[2]刘玉振.孟鲁司特治疗支气管哮喘的临床研究[J].医学信息,2018,31(10):140.[doi:10.3969/j.issn.1006-1959.2018.10.047]
　LIU Yu-zhen.Clinical Study of Montelukast in the Treatment of Bronchial Asthma[J].Medical Information,2018,31(02):140.[doi:10.3969/j.issn.1006-1959.2018.10.047]
[3]曾穗茹,王蓉梅.孟鲁司特联合布地奈德雾化吸入用于肺炎支原体感染后慢性咳嗽患儿的效果观察[J].医学信息,2018,31(19):137.[doi:10.3969/j.issn.1006-1959.2018.19.041]
　ZENG Sui-ru,WANG Rong-mei.Efficacy of Montelukast Combined with Budesonide Aerosol Inhalation in Children with Chronic Cough after Mycoplasma Pneumoniae Infection[J].Medical Information,2018,31(02):137.[doi:10.3969/j.issn.1006-1959.2018.19.041]
[4]陈小军.布地奈德联合噻托溴铵治疗哮喘-慢阻肺重叠综合征的疗效[J].医学信息,2020,33(06):154.[doi:10.3969/j.issn.1006-1959.2020.06.051]
　CHEN Xiao-jun.Efficacy of Budesonide Combined with Tiotropium Bromide in the Treatment of Asthma-COPD Overlap Syndrome[J].Medical Information,2020,33(02):154.[doi:10.3969/j.issn.1006-1959.2020.06.051]
[5]聂优华,刘育斌.孟鲁司特联合普米克令舒吸入剂治疗小儿哮喘的疗效及对患儿炎性因子的影响[J].医学信息,2022,35(20):130.[doi:10.3969/j.issn.1006-1959.2022.20.035]
　NIE You-hua,LIU Yu-bin.Effect of of Montelukast Combined with Pulmicort Respules Inhalation in Treatment of Pediatric Asthma and its Influence on Inflammatory Factors[J].Medical Information,2022,35(02):130.[doi:10.3969/j.issn.1006-1959.2022.20.035]
[6]孙 茜.布地奈德福莫特罗联合噻托溴铵吸入剂治疗慢性阻塞性肺疾病的疗效[J].医学信息,2022,35(20):60.[doi:10.3969/j.issn.1006-1959.2022.20.014]
　SUN Qian.Efficacy of Budesonide Formoterol Combined with Tiotropium Bromide Inhalation in the Treatment of Chronic Obstructive Pulmonary Disease[J].Medical Information,2022,35(02):60.[doi:10.3969/j.issn.1006-1959.2022.20.014]
[7]杨一民,黄小玲,李 溦,等.LTA4H基因多态性对汉族儿童支气管哮喘患者使用孟鲁司特钠疗效及肺功能的影响[J].医学信息,2022,35(20):49.[doi:10.3969/j.issn.1006-1959.2022.20.011]
　YANG Yi-min,HUANG Xiao-ling,LI Wei,et al.Effect of LTA4H Gene Polymorphism on the Efficacy and Lung Function of Montelukast Sodium in Chinese Han Children with Bronchial Asthma[J].Medical Information,2022,35(02):49.[doi:10.3969/j.issn.1006-1959.2022.20.011]
[8]曹进明.噻托溴铵与异丙托溴铵治疗慢阻肺的效果及对患者血清炎症因子的影响[J].医学信息,2022,35(21):131.[doi:10.3969/j.issn.1006-1959.2022.21.034]
　CAO Jin-ming.Effect of Tiotropium Bromide and Ipratropium Bromide in the Treatment of Chronic Obstructive Pulmonary Disease and its Effect on Serum Inflammatory Factors[J].Medical Information,2022,35(02):131.[doi:10.3969/j.issn.1006-1959.2022.21.034]
[9]王丽丽,石景瑜,张 敏.布地奈德福莫特罗联合噻托溴铵治疗慢阻肺稳定期的临床疗效及药理学分析[J].医学信息,2022,35(23):136.[doi:10.3969/j.issn.1006-1959.2022.23.028]
　WANG Li-li,SHI Jing-yu,ZHANG Min.Clinical Efficacy and Pharmacological Analysis of Budesonide Formoterol Combined with Tiotropium Bromide in the Treatment of Stable Chronic Obstructive Pulmonary Disease[J].Medical Information,2022,35(02):136.[doi:10.3969/j.issn.1006-1959.2022.23.028]
[10]王浩凌,李冬琼,吴 旭,等.布地奈德联合噻托溴铵治疗慢阻肺的效果及对CRP、SaO2、pH水平的影响[J].医学信息,2023,36(06):143.[doi:10.3969/j.issn.1006-1959.2023.06.031]
　WANG Hao-ling,LI Dong-qiong,WU Xu,et al.Effect of Budesonide Combined with Tiotropium Bromide in the Treatment of Chronic Obstructive Pulmonary Disease and its Effect on CRP,SaO2 and pH Levels[J].Medical Information,2023,36(02):143.[doi:10.3969/j.issn.1006-1959.2023.06.031]

更新日期/Last Update: 2020-01-15